{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:02:01Z","timestamp":1790186521775,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.xops.2023.100442","type":"journal-article","created":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T10:48:08Z","timestamp":1701600488000},"page":"100442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9441-4356","authenticated-orcid":false,"given":"Robyn","family":"Guymer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voraporn","family":"Chaikitmongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-3734","authenticated-orcid":false,"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-4146","authenticated-orcid":false,"given":"Varun","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Finger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gallego-Pinazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Koh Hock","family":"Chuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3233-1272","authenticated-orcid":false,"given":"Monica","family":"L\u00f6vestam-Adrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Parravano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose D.","family":"Luna Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-9942","authenticated-orcid":false,"given":"Steffen","family":"Schmitz-Valckenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7467-9947","authenticated-orcid":false,"given":"Veeral","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Souied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5657-5979","authenticated-orcid":false,"given":"Gloria C.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Gilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Glittenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Scheidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bengus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2023.100442_bib1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12886-020-01554-2","article-title":"Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems","volume":"20","author":"Finger","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.xops.2023.100442_bib2","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.ophtha.2014.12.007","article-title":"Visual impairment and blindness avoided with ranibizumab in Hispanic and non-Hispanic Whites with diabetic macular edema in the United States","volume":"122","author":"Varma","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100442_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10654-019-00560-z","article-title":"Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis","volume":"35","author":"Li","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.xops.2023.100442_bib4","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.xops.2023.100442_bib5","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2023.100442_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000505070","article-title":"Impact of intravitreal ranibizumab therapy on vision outcomes in diabetic macular edema patients: a meta-analysis","volume":"243","author":"Falc\u00e3o","year":"2020","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.xops.2023.100442_bib7","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/eye.2017.143","article-title":"Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set","volume":"31","author":"Lotery","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2023.100442_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","article-title":"SIERRA-AMD: A retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States","volume":"4","author":"Khanani","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2023.100442_bib9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/aos.13539","article-title":"Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register","volume":"95","author":"Westborg","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2023.100442_bib10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100442_bib11","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ophtha.2016.07.037","article-title":"UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) users group report IV: incidence of blindness and sight impairment in ranibizumab-treated patients","volume":"123","author":"Johnston","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100442_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12886-017-0401-y","article-title":"Demographics of patients receiving intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials","volume":"17","author":"Ziemssen","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.xops.2023.100442_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2023.100442_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40942-023-00463-y","article-title":"REal-world treatment outcomes after delayed intravitreal therapy in center-involving diabetic macular edema - RETORT study","volume":"9","author":"Chitturi","year":"2023","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.xops.2023.100442_bib15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","article-title":"Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents","volume":"138","author":"Evans","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2023.100442_bib16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/PPA.S347713","article-title":"Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study","volume":"16","author":"Giocanti-Aur\u00e9gan","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.xops.2023.100442_bib17","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jamaophthalmol.2021.4103","article-title":"Lapses in care among patients assigned to ranibizumab for proliferative diabetic retinopathy: a post hoc analysis of a randomized clinical trial","volume":"139","author":"Maguire","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2023.100442_bib18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3928\/23258160-20211018-01","article-title":"Race and socioeconomic status in anti-VEGF treatment of diabetic macular edema","volume":"52","author":"Malhotra","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.xops.2023.100442_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100442_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S269162","article-title":"Ten-year real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration","volume":"15","author":"Cheema","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2023.100442_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/jamaophthalmol.2017.0830","article-title":"Prevalence of undiagnosed age-related macular degeneration in primary eye care","volume":"135","author":"Neely","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2023.100442_bib22","first-page":"1573","article-title":"ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD)","volume":"104","author":"Liakopoulos","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2023.100442_bib23","unstructured":"Global Trends in Retina Survey. Chicago, IL: American Society of Retina Specialists;\u00a02022."},{"key":"10.1016\/j.xops.2023.100442_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12886-019-1208-9","article-title":"Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy - a systematic approach to identify and characterize data sources","volume":"19","author":"Daien","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.xops.2023.100442_bib25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100442_bib26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jcjo.2021.10.008","article-title":"Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis","volume":"58","author":"MacCumber","year":"2023","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.xops.2023.100442_bib27","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.xops.2023.100442_bib28","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.xops.2023.100442_bib29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2023.100442_bib30","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.xops.2023.100442_bib31","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41433-020-1048-0","article-title":"An open-source data set of anti-VEGF therapy in diabetic macular oedema patients over 4 years and their visual acuity outcomes","volume":"35","author":"Kern","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2023.100442_bib32","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","article-title":"Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study","volume":"40","author":"Holz","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.xops.2023.100442_bib33","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ophtha.2020.02.027","article-title":"Management and outcomes for neovascular age-related macular degeneration: analysis of United States electronic health records","volume":"127","author":"Kiss","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100442_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233595","article-title":"Effectiveness and safety of ranibizumab 0.5 mg in treatment-naive patients with diabetic macular edema: results from the real-world global LUMINOUS study","volume":"15","author":"Mitchell","year":"2020","journal-title":"PLOS ONE"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914523001744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914523001744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:08:41Z","timestamp":1753816121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914523001744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2666914523001744"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2023.100442","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2023.100442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100442"}}